Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 3
1994 1
1999 1
2006 1
2007 1
2008 1
2010 1
2011 1
2016 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Aztreonam adverse reactions.
Fekete T, Marcelo L, Kreter B. Fekete T, et al. Among authors: kreter b. DICP. 1990 Apr;24(4):438. doi: 10.1177/106002809002400418. DICP. 1990. PMID: 2327118 No abstract available.
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R; AI463026 BEHoLD Study Group. Sherman M, et al. Among authors: kreter b. Gastroenterology. 2006 Jun;130(7):2039-49. doi: 10.1053/j.gastro.2006.04.007. Gastroenterology. 2006. PMID: 16762627 Clinical Trial.
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Sherman M, et al. Among authors: kreter b. Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323. Hepatology. 2008. PMID: 18537189 Clinical Trial.
Hepatitis C pharmacogenetics: state of the art in 2010.
Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB; Pharmacogenetics and Hepatitis C Meeting Participants. Afdhal NH, et al. Hepatology. 2011 Jan;53(1):336-45. doi: 10.1002/hep.24052. Hepatology. 2011. PMID: 21254181 Review.
17 results